Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III)

Journal of Inorganic Biochemistry

Volumn 78, Issue 4, 2000, Pages 341-346

  Trynda Lemiesz, Lilianna ^a   Karaczyn, Aldona ^a   Keppler, Bernhard K ^b   Kozlowski, Henryk ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bilirubin binding; Circular dichroism; Fluorescence quenching; Heme; Human serum albumin; Ruthenium(III)

Indexed keywords

HUMAN SERUM ALBUMIN; RUTHENIUM COMPLEX;

ARTICLE; BILIRUBIN BINDING; BINDING SITE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY;

BILIRUBIN; CHROMATOGRAPHY; CIRCULAR DICHROISM; DEXTRANS; HEME; HUMANS; INDAZOLES; MODELS, CHEMICAL; ORGANOMETALLIC COMPOUNDS; PROTEIN BINDING; PROTEIN CONFORMATION; SERUM ALBUMIN; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY; ULTRAVIOLET RAYS; WARFARIN;

EID: 0034737805     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-0134(00)00062-3     Document Type: Article

References (32)

1. M.J. Clarke, Progress in Clinical Biochemistry and Medicine, vol. 10, Springer, Berlin, 1989, pp. 25-39.
2. B.K. Keppler, G. Lipponer, B. Stenzel, F. Kranz, in: B.K. Keppler (Ed.), Metal Complexes in Cancer Chemotherapy, VCH, Weinheim, 1993, pp. 187-220.
3. Keppler B.K., Hartmann M. Met. Based Drugs. 1:1994;145.
4. F. Kratz, N. Mulinacci, L. Messori, I. Bertini, B.K. Keppler, in: J. Anastassopoulou, Ph. Collery, J.C. Etienne, Th. Theophanides (Eds.), Metal Ions in Biology and Medicine, vol. 2, J. Libbey Eurotext, Paris, 1992, pp. 69-74.
5. Kratz F., Keppler B.K., Messori L., Smith C., Baker E.N. Met. Based Drugs. 1:1994;169.
6. Kratz F., Hartmann M., Keppler B.K., Messori L. J. Biol. Chem. 269:1994;2581.
7. Kratz F., Messori L. J. Inorg. Biochem. 49:1993;79.
8. He X.M., Carter D.C. Nature. 358:1992;209.
9. Carter D.C., Ho J.X. Adv. Protein Chem. 45:1994;153.
10. Peters Jr T. Adv. Protein Chem. 37:1985;161.
11. Sudlow G., Birkett D.J., Wade D.N. Mol. Pharmacol. 12:1976;1052.
12. Soltys B.J., Hsia J.C. J. Biol. Chem. 253:1978;3023.
13. Sadler P.J., Viles J. Inorg. Chem. 35:1996;4490.
14. Beaven G.H., Chen S.H., d'Albis A., Gratzer W.B. Eur. J. Biochem. 41:1974;539.
15. Blauer G., Harmatz D., Snir J. Biochem. Biophys. Acta. 279:1972;68.
16. Keppler B.K., Henn M., Juhl U.M., Berger M.R., Niebl R., Wagner F.E. Prog. Clin. Biochem. Med. 10:1989;41.
17. S.F. Mason, Molecular Optical Activity and the Chiral Discrimination, Cambridge University Press, Cambridge, UK, 1982.
18. Trynda-Lemiesz L., Keppler B.K., Kozlowski H. J. Inorg. Biochem. 73:1999;123.
19. Ohta N., Chen D., Ito S., Futo T., Yotsuyangi T., Ikeda K. Int. J. Pharmaceut. 118:1995;85.
20. Trynda-Lemiesz L., Pruchnik F. J. Inorg. Biochem. 66:1997;187.
21. D. Freifelder, Physical Biochemistry: Applications to Biochemistry and Molecular Biology, W.H. Freeman, San Francisco, CA, 1976, pp. 410-443.
22. Peters Jr T. Clin. Chem. 23:1977;5.
23. Hrkal Z., Kodiczek M., Vodrazka Z., Meloun B., Moravek L. Int. J. Biochem. 9:1978;349.
24. G. Blauer, D. Harmatz, A. Naparstek, FEBS Lett. (1970) 53.
25. Trynda L., Przywarska-Boniecka H., Kosciukiewicz T. Inorg. Chim. Acta. 135:1987;55.
26. Beaven G.H., d'Albis A., Gratzer W.B. Eur. J. Biochem. 33:1976;500.
27. Bos O.J.M., Remijn J.P.M., Fisher J.E., Witing J., Janssen L.H.M. Biochem. Pharmacol. 37:1988;3905.
28. Fehske K.J., Muller W.E., Wollert U. Mol. Pharmacol. 16:1979;778.
29. Sadler P.J., Tucker A., Viles J.H. Eur. J. Biochem. 220:1994;193.
30. Zgirski A., Frieden E. J. Inorg. Biochem. 39:1990;137.
31. Bal W., Christodoulou J., Sadler P.J., Tucker A. J. Inorg. Biochem. 70:1998;33.
32. Takahashi I., Ohnuma T., Kavy S., Bhardwaj S., Holland J.F. Br. J. Cancer. 41:1980;602.